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Recent genetic mapping and gene-phenotype studies have revealed the genetic architecture of type 1
diabetes. At least ten genes so far can be singled out as strong causal candidates. The known functions
of these genes indicate the primary etiological pathways of this disease, including HLA class II and I mole-
cules binding to preproinsulin peptides and T cell receptors, T and B cell activation, innate pathogen-viral
responses, chemokine and cytokine signaling, and T regulatory and antigen-presenting cell functions. This
review considers research in the field of type 1 diabetes toward identifying disease mechanisms using
genetic approaches. The expression and functions of these pathways, and, therefore, disease susceptibility,
will be influenced by epigenetic and environmental factors. Certain inherited immune phenotypeswill be early
precursors of type 1 diabetes and could be useful in future clinical trials.Nature and Nurture
The incidence of type 1 diabetes (T1D) has risen steadily in
developed countries from the 1950s to the present day, with
the recent, alarming prediction that it will double in children
under age 5 years by 2020 (Patterson et al., 2009). We have no
knownway of preventing this pandemic. There seems little doubt
that T1D is a ‘‘disease of civilization,’’ with numerous alterations
to our environment since the 1940s and 1950s, including sanita-
tion, healthcare, and diet (Bach, 2002; Cooke, 2009; Farquhar
et al., 2010; Zipitis and Akobeng, 2008). These nature or nurture
environmental changes, which were proposed in 1991 as causes
of reductions of T1D protective factors (Todd, 1991), are ongoing
and, in countries such as the UK and USA, are unlikely to be the
same now compared to the 1950s and 1960s. Identification of
the genes, molecules, cells, and pathways involved in T1D, i.e.,
the nature component (Figures 1 and 2), will not only elucidate
disease mechanisms but also help identify the environmental
factors that could act in utero, in the first 3 years of life (Siljander
et al., 2009) and thereafter, leading to the inflammatory events
immediately preceding diagnosis (Wang et al., 2008).
T1D research is dominated partly by the search for environ-
mental ‘‘triggers’’ of the disease. However, it is well established
that the frequency in the mouse and rat models of T1D is much
higher in germ-free living conditions compared to specific path-
ogen-free or infection-prone conditions (Bach, 2002; Todd,
1991;Wen et al., 2008). No exogenous factor or infectious trigger
is actually required. I propose that T1D genetically identical (or
monozygotic) twins would be much more concordant for T1D
than the average 50% recorded in standard environmental
conditions if, in the wholly unlikely scenario, they could be reared
germ-free. Concordance would be much higher in twin pairs
carrying the strongest susceptibility genotypes, for example, if
twins were all HLA-DRB1*03-DRB1*0401-DQB1*0302 heterozy-
gous genotype and also carrying the susceptible alleles for the
top five non-HLA loci (Figure 2). It is already known that if twins
with evidence of autoimmunity are followed for long enough,
concordance is over 50% (Redondo et al., 2008). Preclinical
autoimmunity in T1D occurs naturally and spontaneously just
as soon as the immune system, by about 12 months, is suffi-ciently mature tomount an autopathogenic response, with exog-
enous factors altering disease penetrance as cofactors, but not
being absolutely necessary. A child could carry well above the
average number of the susceptibility alleles for T1D but be living
in a very protective environment and, therefore, not develop the
disease. Conversely, another child and their mother could live in
a very T1D-permissive modern-day environment and carry just a
few protective alleles of the T1D loci that would reduce the
disease risk of that child to well below the population average
(0.1%–1%). A current goal is to identify modifiable environmental
factors or therapeutics that mimic the effects of protective
factors or alleles. T1D is not the only immune disease that has
become a major chronic disorder of childhood, with the
pandemic of allergy (e.g., peanuts) and asthma being even
more dramatic (Bach, 2002; Clark et al., 2009). Our immune
systems are not exposed to the same infectious, immunostimu-
latory environment they evolved to cope with during the 7 million
years of human evolution. If this period was 24 hr, only in the last
half second has westernization thrown a highly polymorphic,
functionally diverse genetic immune system, which evolved to
wage war against infections into a much more hygienic, less
infectious environment, in which people’s immune systems are
relatively less well stimulated and regulated. Infection leads to
the induction and action of negative immunoregulatory genes
(e.g., IL2, the indispensible function of which is to maintain
immunoregulation via T regulatory cells, and CTLA4; Figures 1
and 2) to switch off antimicrobial immune responses in order to
avoid unnecessary tissue damage and autoimmunity.
During infancy, the immune system may be provoked with
a massive rebuilding of the pancreatic islets and their beta cells
via a naturally programmed cell death or apoptosis (Li et al.,
2008; Turley et al., 2003). In children genetically susceptible to
T1D with reduced immune tolerance to islet antigens including
preproinsulin (PPI), these events could be endogenous initiating
factors of disease not requiring exogenous factors.
HLA Molecules and Insulin Peptides
The categorization of pediatric T1D as an autoimmune disease is
not ambiguous, with the presence of the predisposing HLA classImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 457
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Figure 1. A Model for the Pathogenesis
of Type 1 Diabetes Based on Genetic
Etiological Studies in Humans
Shown are genes (e.g. those that encode MHC
HLA class II and class I antigen-presentationmole-
cules, preproinsulin (INS) in the thymus, CTLA-4 in
Treg cells, cytokines) believed to be causal in the
process of type I diabetes. Also shown are influ-
ences of viral infections and type 1 interferon
(IFN) production and effects; autoimmune reper-
toire development in the thymus; and the main
immune cell types, CD4+ and CD8+ T cell subsets,
T regulatory (Treg) cells, and B cells and various
other antigen-presenting cells, acting together to
kill pancreatic b cells. Adapted from (von Herrath,
2009).
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90% of cases and the presence of autoantibodies and, more
recently, autoreactive, anti-islet antigen-specific T cells (Sko-
wera et al., 2008) in the circulation of prediabetic individuals
and of newly diagnosed and established cases. Transgenic
mouse modeling (Mellanby et al., 2008; Nakayama et al., 2005)
has provided direct support that it is the peptide-binding activity
of the HLA class II molecules in antigen-presenting cells (APCs)
for T lymphocyte peptide recognition that is themainmechanism
of action of the DR and DQ molecules in T1D etiology. This is by
far the major determinant of disease in the genome (Cucca et al.,
2001; Zhang et al., 2008). In humans (and mice), susceptibility
and resistance to T1D has been mapped to particular polymor-
phic peptide-binding pockets of the DQ molecule, pocket 9,
and of DR, pockets 1 and 4 (and their mouse orthologs, IA and
IE, respectively) (Cucca et al., 2001; Suri et al., 2005). It remains
a goal to identify molecules that modulate the function of these
pockets and could be therapeutic.
Recent fine mapping of the extended MHC region, 8 Mb of
chromosome 6p21, which was made possible by the develop-
ment of high-throughput, dense, and genome-wide single
nucleotide polymorphism (SNP) genotyping (referred to as
genome-wide association studies, GWAS), has confirmed that
the major susceptibility, and resistance, to T1D does indeed
map to the HLA class II region of the MHC (Howson et al.,
2009; Nejentsev et al., 2007). Class II molecules in APCs bind
peptides from the currently identified autoantigens, preproinsulin
(PPI), insulinoma-associated antigen 2 (I-A2), glutamic acid de-
carboxylase (GAD), and zinc transporter (ZnT8) (Wenzlau et al.,
2008), and present these to CD4+ T cell antigen receptors
(TCRs) in the thymus and in the periphery, for example, in pancre-458 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.atic lymph nodes and within the islets
themselves (Figure 1) (von Herrath, 2009).
CD4+ T cells provide help to CD8+ cyto-
toxic T cells, which are the widely
accepted most important killer of human
islet beta cells in T1D autoimmunity (Sko-
wera et al., 2008; Willcox et al., 2009).
This long-awaited comprehensive ge-
netic mapping also showed that T1D
susceptibility is modified, however, by
lesser but still important effects of the
specific allotypes of the equally polymor-phic HLA class I molecules, HLA-B and HLA-A (Howson et al.,
2009; Nejentsev et al., 2007). These molecules present peptides
tocytotoxicCD8+Tcells andareexpressedstrongly in thepancre-
atic insulin-producing beta cells (von Herrath, 2009). These recent
HLA class I associations with T1D and additional histological
evidence (Willcox et al., 2009) help secure a central role for CD8+
T cells and their helpers, CD4+ T cells and APCs, in T1D etiology.
Preproinsulin has emerged as the most important autoantigen
in childhood-onset T1D (Skowera et al., 2008), a widely held
conclusion that is underpinned by the long-known and very
strong association of a promoter polymorphism of the insulin
structural gene (INS) (Vafiadis et al., 1997). Circulating cytotoxic
CD8+ T cells have been characterized that recognize part of the
N-terminal signal peptide and the peptidase cleavage site of the
PPImolecule, residues PPI15–24, bound to theHLA-A*0201mole-
cule (Skowera et al., 2008). Once class II variation has been
taken into account statistically, this allele has recently been
shown to be one of the predisposing alleles of HLA-A (Howson
et al., 2009; Nejentsev et al., 2007). The connection of T1D
with the signal peptide of PPI was predicted in a correlative anal-
ysis of HLA class II DQ structure and peptide-binding pocket
characteristics with PPI sequences in which the PPI 8–16 signal
sequence was highlighted, in addition to the T1D-associated
insulin B chain sequence 9–23 (Cucca et al., 2001; Mohan
et al., 2010; Nakayama et al., 2005). It will be of interest to
analyze the PPI peptides that bind to other class I and class II
alleles. It remains to be shown experimentally if the T1D-protec-
tive DQ6molecule (encoded by the DQA1*0102 and DQB1*0602
alleles) bound to PPI8–16 is indeed protective via thymic dele-
tion or reprogramming of autoreactive T cells (Fan et al., 2009;
Vafiadis et al., 1997), and/or protective natural regulatory T cell
Figure 2. Currently Mapped Type 1 Non-HLA Diabetes Loci and Candidate Causal Genes where Known
Current type 1 diabetes loci, their chromosome location, the most disease-associated SNP and, for 15 of them, the most likely causal gene in the locus, as sup-
ported by current functional evidence, e.g., IL2RA (Dendrou et al., 2009) (http://www.t1dbase.org/page/Regions).
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should be included in future efforts to prevent the disease by
trying to restore immune tolerance to PPI (Arai et al., 2010).
Tolerance induction prevention trials have been conducted
using mature insulin, with no success so far (Bonifacio et al.,
2008; Na¨nto¨-Salonen et al., 2008). This could be due to several
factors, including a timing of treatment too late in a disease
process that may well have rapid epitope and antigen spreading
in 2- to 3-year-old children (Siljander et al., 2009) or possibly the
generation of incorrect epitopes (for example, no N-terminal PPI
sequence included), as well as inappropriate dosages. Inevi-
tably, a goal of neonatal tolerance to PPI in newborns by vacci-
nation would be a desirable approach. Nevertheless, one trial,
pre-Point, has been initiated to try to prevent the appearance
of IAA by oral ingestion of mature insulin with differing doses
(Bonifacio et al., 2008), and PPI could be considered as an addi-
tional arm, especially because recombinant protein or peptides
can be made (Berg et al., 1993).
So far, there is no convincing evidence for genetic association
of other mapped candidate genes across the genome (aside
from INS) encoding autoantigens with T1D susceptibility (www.
t1dbase.org). Recent genetic mapping raises an intriguinghypothesis that the GLIS3 transcription factor could be a T1D
autoantigen. Rare monogenic permanent neonatal diabetes
can be caused by mutations in this beta cell-expressed gene
(Sene´e et al., 2006), and very recently, it has been associated
with fasting glucose levels and type 2 diabetes (T2D) suscepti-
bility (Dupuis et al., 2010). Therefore, this would be the first
convincing example of a gene predisposing to both T1D and T2D
(Rafiq et al., 2008; Raj et al., 2009). This might be because of
its function in beta cell development and/or function, or perhaps
it could be an autoantigen in T1D for which polymorphism in or
near the gene alters its expression, as found for INS (Vafiadis
et al., 1997). Otherwise, T2D and T1D are genetically and, there-
fore, etiologically distinct (Rafiq et al., 2008; Raj et al., 2009).
After taking into account the effects of the HLA class II and
class I polymorphic peptide-binding amino acids, there is little
statistical power left to detect other effects in the MHC, if they
exist (Howsonet al., 2009;Nejentsev et al., 2007). Such investiga-
tionswill require larger sample sets of cases, controls, andwhere
possible, families. Nevertheless, there is some, but not yet
convincing, evidence of residual effects after HLA conditioning,
of which the most intriguing is a potential association of SNPs
(e.g., SNP rs9268831) near the class II gene,HLA-DRA (encodingImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 459
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et al., 2007). The same SNPs have been associated with alter-
ation of the amounts of RNA from the HLA-DQA1 and HLA-
DRB1 genes, a so-called expression quantitative trait locus
(eQTL; SNP rs9268645, which is strongly associated with
rs9268831) (Dixon et al., 2007). It has been anticipated for
decades that polymorphic expression differences of the class II
molecules should alsoalter susceptibility toT1D, and this hypoth-
esis is now worth re-exploring.
Several mysteries remain for the function of HLA molecules in
T1D. For example, which specific peptides (from the known
autoantigens) does the most T1D-predisposing DQ transhetero-
dimer, DQA1*0501/DQB1*0302, bind? (Koeleman et al., 2004)
This transdimer is encoded by the highest risk genotype,
DRB1*03-DRB1*0401-DQB1*0302, present in 1%–2% of
general (European) populations and over 30% of people with
T1D. This genotype not only alters susceptibility but is also asso-
ciated with a lower age-at-diagnosis (Howson et al., 2009;
Nejentsev et al., 2007), indicating its primacy in the earliest
events in anti-beta cell autoimmunity. Another unresolved issue
is thatDRB1*03 and DRB1*04-DQB1*0302 haplotypes are asso-
ciated with GADA, and IA-2A and IAA, respectively (Kordonouri
et al., 2010). Yet, this heterozygous genotype does not, so far,
associate strongly with T1D autoantibodies. Perhaps this geno-
type encodes a combination of HLA class II (and class I) gene
alleles that fuels an APC-, CD4+ T cell-, and CD8+ T cell-driven
cellular attack on beta cells that is not as dependent as other
or later autoimmune responses that include B lymphocytes as
APCs. The DQ transdimer may present peptides from antigens
not so far studied in T1D (Stadinski et al., 2010). For example,
compared to other immune diseases, little attention has been
paid to the analysis of endogenously or environmentally modified
antigens (Stadinski et al., 2010), as observed in rheumatoid
arthritis with citrullination (Wegner et al., 2010) and in celiac
disease and transglutaminase (Jabri and Sollid, 2009).
The role of B cells by way of their function as antigen-present-
ing cells in T1D etiology is now widely accepted (Pescovitz et al.,
2009). The basis of this consensus includes recent convincing
histology (Willcox et al., 2009). Also, occurrence of multiple
autoantibodies is a highly specific and sensitive predictor of
impending T1D diagnosis, although it is still believed that these
autoantibodies themselves are not pathogenic (Bingley, 2010).
Several of the strongly suspected causal T1D genes and other
candidates in the now over 50 associated chromosome regions
(Figure 2) (www.t1dbase.org) are strongly and selectively ex-
pressed in B cells, e.g., BACH2, encoding a B cell-specific tran-
scription factor, on chromosome 6q15 (http://biogps.gnf.org/
#goto = genereport&id = 60468). Further research is required
to determine the role of BACH2 in T1D. Note that there is
evidence, as for almost all genes, for expression and functions
in other cell types, e.g., IFIH1 (Wang et al., 2010) and BACH2
(Lesniewski et al., 2008).
Other Pathways
So far, I have emphasized the central role for APC-peptide-T cell
interaction in T1D. However, as demonstrated in NOD mice, the
diabetogenicity of the HLA-DQ ortholog, IA, is completely
dependent not only on the environment, but also on the alleles
of multiple genes across the genome (Wicker et al., 2005). The460 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.strongest single non-MHC locus called Idd3 on mouse chromo-
some 3, for which homozygosity of the T1D resistance allele
provides over 70% protection, despite full NOD MHC IAg7
susceptibility (Yamanouchi et al., 2007). Because a functional
phenotype of the NOD allele of this locus was identified, namely
reduced T regulatory cell function, and this was recapitulated by
heterozygosity of the IL-2 gene-deficient genotype (Yamanouchi
et al., 2007), correlations between reduced IL-2 expression of the
NOD and NOD-like Il2 alleles versus non-disease-associated
alleles indicated that the causal gene for Idd3 is Il2. The causal
SNPs alter Il2 transcription (Yamanouchi et al., 2007). However,
there is controversy here that needs to be resolved because the
gene next to Il2 is Il21, which also has key roles in the immune
system. IL-21, for example, functions in the development of
the pathogenic Th17 subset, and inmurine autoimmune disease,
including T1D, it is required, as shown by knocking out the gene
by homologous recombination in mice (McGuire et al., 2009;
Sutherland et al., 2009).
The genetics of the orthologous or syntenic region of the
human genome, chromosome 4q27, may be informative in this
ongoing debate. Celiac disease (Dubois et al., 2010), juvenile
idiopathic arthritis (Hinks et al., 2010), and rheumatoid arthritis
(Raychaudhuri et al., 2009) all map most strongly to a SNP,
rs6822844: G > T (T is the minor allele associated with reduced
risk of these diseases, or the common allele, G, being associated
with increased susceptibility), situated 10 kb50 of the 30 end of the
IL-21 gene and 130 kb 30 of the 50 end of the IL-2 gene. Whereas,
so far, only T1Dmaps convincingly to the exon 1 common synon-
ymous SNP of IL2 (rs2069763: G > T), with no evidence for
association with the other diseases based on currently available
information (Smyth et al., 2008). It remains to be shown convinc-
ingly if this SNP marks IL2 haplotypes with varying IL2 mRNA
expression and protein production and/or IL2 haplotypes that
correlate with relevant immune cell phenotypes (Matesanz
et al., 2004). Serum levels of IL-21 have been associated with
the induction of the autoimmune thyroid disease, Graves’
disease, and in MS patients treated with the anti-T cell antibody,
Campath-1H (Jones et al., 2009). They also showed that the
immune-disease-predisposing G allele of the 50 IL21 SNP
rs6822844 was associated with increased serum IL-21. There-
fore, in humans, increased IL-21 production might predispose
the individual to a number of immune-inflammatory diseases,
but not to T1D specifically. In NODmice, in contrast, IL-21 levels
may bemore critical, whichwould be consistent with the fact that
NOD mice develop polyendocrine autoimmunity.
The gene encoding the high-affinity a chain (CD25) of the
three-chain IL-2 receptor, IL2RA on chromosome 10p14, is
also strongly associated with T1D with evidence for at least
two distinct causal variants (Dendrou et al., 2009). Correlations,
first with soluble CD25 in serum and plasma (Lowe et al., 2007),
and then with mRNA (Dendrou et al., 2009), and with CD25
surface expression (Dendrou et al., 2009), indicate unequivocally
that IL2RA is a causal gene in this chromosome region. T1D-pre-
disposing alleles of SNPs in intron 1 and the 50 region of the gene
lower transcription, which results in lower amounts of CD25 on
the surface of memory CD4+ T cells and also in number of
CD25+ naive CD4+ T cells (Dendrou et al., 2009). One of the
notable results to come out of this large-scale clinical study
was that the expression of CD25 on memory T cells was highly
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(Dendrou et al., 2009) and, thus, strongly heritable, indicating
that here is an immunophenotype that is hard-wired into the
human genome. For the 1% of the British population that have
the most protective IL2RA genotype and most CD25 on these
memory cells, there is considerable protection from T1D (note
its dominance in Figure 2 in the top ten loci). Memory CD4+
T cells with more CD25 on their surface secrete more IL-2 on
stimulation (in PBMCs stimulated with the superantigen SEB),
and hence, it is possible that T cells are a source for IL-2, which
could promote Treg cell function (Dendrou et al., 2009).
The gene encoding the b-chain of the IL-2 receptor, IL2RB
on chromosome 22q12, has been associated convincingly with
RA (at p < 5 3 108) (Raychaudhuri et al., 2009). Given this prior
evidence, we can now conclude with confidence that the current
support for association of this locus with T1D (p < 104; http://
www.t1dbase.org/page/Overview/display/marker_id/rs3218253,
with the most associated T1D SNP being rs9622555 at p =
7.9 3 107; http://www.t1dbase.org/page/Overview/display/
marker_id/rs9622555) is highly likely to be a true effect because
IL2RB is convincingly associated with RA and also shows
evidence of association with T1D, and the two diseases occur
together in patients and in families more than expected based
on their prevalence in the general population. Human geneticists
now know empirically that an association with p% 5 3 108 in
a large, robustly analyzed sample set is highly likely to be
a true effect. In a comparison of T1D with celiac disease (Smyth
et al., 2008), which shows remarkable sharing of susceptibility
loci, a conservative threshold of p < 104 was selected to indi-
cate that if a locus has been associated with p < 5 3 108 in
one immune-mediated disease then if it has p < 104 or less
for T1D, it is highly unlikely to be a false-positive result. Neverthe-
less, until more information is gained regarding correlations of
the IL2RB disease-associated SNPs with RNA, protein, or
cellular phenotypes, we need to be cautious and conclude that
IL2RB is a very good candidate, given what we know about the
genetics and functions of other genes in the immediate IL-2
signaling pathway in T1D.
From these results in T1D for the IL-2 and IL-2R genes, one
can ask the question: with such fundamental molecules being
altered in the immune system, both of which are essential for
immune tolerance, why are several immune diseases not associ-
ated with these variants? Note that IL2RA is associated with MS
(Maier et al., 2009). However, the associations of SNPs within or
near the gene are different from that of T1D. For example, the
most associated T1D, SNP rs12722495, which is associated
with a CD25 expression-associated memory CD4 phenotype
(Dendrou et al., 2009), is not associated with MS susceptibility
(Maier et al., 2009). One possible part of the explanation is that
the action of these molecules and the cells involved depends
on the microenvironment of the islets (Tang et al., 2008). Tang
et al. (2008) reported a selective defect in Treg cell survival in
inflamed islets in NODmice (and not in pancreatic lymph nodes),
owing to lower IL-2 production by these mice, which is due in
part to Idd3, as discussed above (Yamanouchi et al., 2007).
Low-dose IL-2 therapy restored a healthy balance between
Treg cells and T effector cells in this mouse model (Tang et al.,
2008). Molecules in the inflamed islets could be downregulating
CD25 (a protease, for example) and inhibiting IL-2 expression(Tang et al., 2008). The balance between the functions of T
effector and Treg cells appears to be important in human T1D
(Lawson et al., 2008; Long et al., 2009).
The CTLA-4 gene is associated with T1D susceptibility (Ueda
et al., 2003), and more recently, its protein product has been
shown to have an essential and specific role in Treg cell function
in mice (Wing et al., 2008). One outstanding question is the role
and function of the isoform of CTLA-4 that is missing the trans-
membrane domain (encoded by exon 3), referred to as soluble
CTLA-4 (Ueda et al., 2003), and which is presumed to be
secreted. The genetic analyses and correlation of CTLA-4 gene
haplotypes with messenger RNA levels suggest that it is a reduc-
tion in the amount of soluble CTLA-4 that is responsible for the
increased susceptibility to T1D (Ueda et al., 2003) in T cells,
including Treg cells (Atabani et al., 2005). As we have noted
already, however, many genes have multiple functions, in
multiple cells and tissues, as described recently for CTLA-4 in
the thymus (Verhagen et al., 2009). Another example of genes
being expressed in multiple different tissues and cell types
with potentially different functions is PTPN22, for which the
effect of the Trp620 common nonsynonymous SNP is undoubt-
edly a causal one in T1D (and several other immune diseases).
Trp620 reduces TCR signaling via the LCK and ZAP70 kinases,
thereby increasing TCR signaling thresholds, which could
affect both T effector cell and Treg cell reactions to self antigens
(Arechiga et al., 2009; Bottini et al., 2006).
Several other cytokine genes appear on the list of genetically
mapped candidate genes (Figure 2 and http://www.t1dbase.
org/page/PosterView/Regions). The IL-10 gene region is asso-
ciated with T1D (Barrett et al., 2009), as it has been for other
diseases, including in inflammatory bowel disease (Crohn’s
and ulcerative colitis) (Franke et al., 2008). In T1D, it appears
that less IL-10 is predisposing (Barrett et al., 2009; Kurreeman
et al., 2004). According to the latest genetic and expression
results, more IL-27 predisposes to T1D (Barrett et al., 2009;
Imielinski et al., 2009); meanwhile, the gene encoding the alpha
chain of the IL-7 cytokine receptor, IL7R (chromosome 5p13.2),
has been associated with MS (Zuvich et al., 2010) and is also
associated with T1D (http://www.t1dbase.org/page/Overview/
display/gene_id/3575). In the IL-7Ra gene, the minor allele of a
SNP that reduces splicing of the transmembrane domain, caus-
ing less soluble IL-7Ra to be made, is protective for T1D (and
MS) (Hoe et al., 2010). Relatively higher amounts of IL-7Ra, IL-
7, and IL-2, and their functions locally in islets, could both help
sustain a healthy T effector cell:Treg cell balance (Tang et al.,
2008). Moreover, the chemokine receptor gene, CCR5, which
has a naturally occurring, albeit rare (1% in populations), func-
tionally disruptive variant, delta32, is associated with protection
from T1D, RA, and celiac disease (Smyth et al., 2008), indicating
the importance of chemokines and T cell trafficking in T1D.
As more and more genes are found for human diseases and
traits, candidate genes for T1D causality will become apparent.
An exciting example of this rapid gain in knowledge is the
SH2B3 gene on chromosome 12q24. This gene was first associ-
ated with T1D (Todd et al., 2007), in which a nonsynonymous
SNP, rs3184504 Arg262Trp, was the most associated marker.
The Trp262 allele is the nonancestral allele altering the sequence
of a predicted functional pleckstrin homology domain (Todd
et al., 2007), suggestive that this could be a causal SNP andImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 461
Table 1. Crohn’s Disease Candidate Susceptibility Genes that
Function in the Th17 Pathway Are Not Associated with
Susceptibility to Human Type 1 Diabetes
Gene Name
T1D Genetic Confirmed Region Expression In Beta
Cells or IsletsHuman Mouse Rat
CCR6 no yes yes
ICOSLG no yes
IL23R no yes
JAK2 no yes yes
STAT3 no yes
The five genes listed have been associated with susceptibility to Crohn’s
disease and are also associated with the development and function
of Th17 cells, indicating the primary importance of this pathway in the
etiology of this inflammatory bowel disease. The Gene Dossier tool in
T1DBase (http://www.t1dbase.org/page/DossierHome) allows research-
ers to enter lists of genes and quickly obtain a range of information, for
example, is the gene in one of the currently mapped type 1 diabetes loci
in human, mouse or rat (‘‘T1D Genetic Confirmed Region’’)? Is the gene
expressed in pancreatic beta cells? These results indicate that the Th17
pathway is not a primary, etiological component of T1D development.
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celiac disease (Hunt et al., 2008) and, most recently, with platelet
count and cardiovascular disease (Soranzo et al., 2009). The
latter study also focused on the Arg262Trp SNP and showed
that the Trp262 allele lies on a very long extended conserved
haplotype for which they provided evidence for very recent
selection in European populations, presumably to help provide
resistance to a pathogen(s) (Soranzo et al., 2009). SH2B3
encodes LNK, an important negative regulator of cell-signaling
events from a number of receptors, including the TCR and
MPL, the latter of which is the receptor for thrombopoietin on
platelets (Soranzo et al., 2009). The knockout mouse phenotype,
which shows hyperproliferation of platelets (Soranzo et al.,
2009), supports the hypothesis that SH2B3 is the disease-causal
gene in this region of chromosome 12q24.
Genes not associated with T1D can also inform on etiology
and have potential clinical implications. In Crohn’s disease
(Van Limbergen et al., 2009), psoriasis, and ankylosing spondy-
litis (Reveille et al., 2010), a set of susceptibility loci encoding
other candidate geneswith known functions in the Th17 pathway
have been reported: IL23R, JAK2, STAT3, CCR6, and ICOSLG.
Using T1DBase and the current SNP association results,
however, there is no evidence that these ‘‘Th17 genes’’ are asso-
ciated with T1D (Table 1). Hence, in agreement with recent NOD
studies (Bending et al., 2009), there is no support for a primary
etiological role for this subset of T cells in T1D. However, this
does not rule out a role for these cells in the state of the immune
system at diagnosis of T1D, which has characteristics of a
broader inflammatory response associated with IL1A, IL1B,
TNF, and IL6 (Wang et al., 2008), similar to that found in some
T2D patients (Larsen et al., 2009). Note that evidence for associ-
ation of variants of these four genes with a variety of inflamma-
tory and other phenotypes has been reported, but none has
been convincingly associated with T1D (www.t1dbase.org).
Nevertheless, recent and ongoing intervention trials of
immunotherapies are currently targeted at newly diagnosed462 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.cases with remaining levels of serum C-peptide (i.e., there is still
residual beta cell insulin secretion). They test drugs to inhibit
inflammation, for example, anti-IL-1 receptor antagonist (ana-
kinra; http://clinicaltrials.gov/ct2/show/NCT00711503), or to
alter T or B cell subsets, such as CD3 or CD20 monoclonal anti-
bodies, respectively (Roep and Peakman, 2010; You et al.,
2008). There is published evidence of some benefit of these
drugs (Keymeulen et al., 2010; You et al., 2008). Taking into
account safety, it appears that repeat dosing will be required
because the autoimmune system will likely reset itself according
to the inherited genetic program, to continue beta cell destruc-
tion and a total loss of C-peptide. It is noted, however, for
some children carrying the most potent and largest doses of
susceptibility alleles across the genome, that beta-cell destruc-
tion will be aggressive and rapid, leaving little or no C-peptide at
diagnosis.
One T1D region has revealed its causal gene from deep, next-
generation resequencing studies (Nejentsev et al., 2009). In
2006, a region on chromosome 2q24.2 was mapped in the first
GWAS in diabetes (Smyth et al., 2006). Its most associated
region contained four genes, one of which was a particular func-
tional candidate, IFIH1, encoding the intracellular pathogen
receptor, MDA5, which had recently been shown in mice to be
essential for the immune response to viral RNA. Most intrigu-
ingly, among the viruses detected by MDA5 are viruses from
the picornavirus family, of which enterovirus is a member.
Enteroviruses, of which coxsackie virus is a member, are one of
the most common types of viruses reported to be associated
with T1D (Dotta et al., 2007). That IFIHI is a T1D causal gene was
confirmedwhen the resequencing of gene exons from 480 cases
with T1D and 480 controls with follow-up genotyping in over
15,000 cases and controls revealed the association of four rare
‘‘knockout’’ functional variants of the gene (Nejentsev et al.,
2009). In addition, these rare variants are associated with protec-
tion fromT1D, indicating that it is the normal or wild-type function
of IFIIH1-MDA5 that predisposes to T1D (Nejentsev et al., 2009).
Binding of viral RNA to MDA5 triggers the production of the
type 1 interferons (a and b), which could, in a highly plausible
scenario, enhance anti-beta cell CD8+ cytotoxic T lymphocyte
(CTL) activity in islets (Figure 1) via HLA class I upregulation on
beta cells, and direct effects on CD4+ and CD8+ T cells (Deven-
dra and Eisenbarth, 2004; Li et al., 2008; von Herrath, 2009).
More recently, the TLR7-TLR8 region of chromosome Xp22.2
has been mapped in T1D (www.t1dbase.org) and in celiac
disease (Dubois et al., 2010). These genes also encode intracel-
lular receptors for viral RNAs and for DNA and RNA from
apoptotic cells (Li et al., 2008). Along with a widening spectrum
of viruses recognized by MDA5, the genetic results suggest
that a variety of virus infections could, via increased type 1 inter-
feron levels, enhance susceptibility to autoimmune beta-cell
destruction and T1D, provided that susceptibility alleles at other
loci are present. Seasonal differences in viral infections,
combined with other seasonal effects such as reduced vitamin
D levels inmore northern countries during thewinter months (Hy-
ppo¨nen and Power, 2007; Svoren et al., 2009), could help explain
the well-established seasonality of T1D diagnosis itself.
However, it seems unlikely that vaccination against one type of
virus will prevent many cases of T1D. The relationship between
virus and susceptibility to chronic disease is really only just
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Reviewbeginning to be investigated, where viruses such as Epstein Barr
Virus and cytomegalovirus could impact T1D and other immune-
mediated diseases (Virgin et al., 2009).
Unknown Mechanisms and Pathways
There are at least ten human T1D regions (Figure 2) for which
there is no compelling functional candidate gene (www.
t1dbase.org). Further gene-phenotype studies are required to
narrow down which genes are involved. For example, the causal
genes are unknown in the following regions: chromosomes
4p15.5, 6q22.32 (C6orf173 is the only gene in the most associ-
ated interval), 7p15.2, 7p12.1, 10q23.31 (renalase, RNLS, is the
only gene in the most associated interval), 14q24.1, 16q23.1,
19q13.32, 20p11, 22q12.2, and Xq28. It will be fascinating to
determine, for example, if C6orf173 and RNLS are potential
causal genes and what their functions are. So far, it is reported
that RNLS makes a protein secreted by the kidney that is
involved in catecholamine metabolism, and in brain function
(Hennebry et al., 2010)—how could this fit into T1D etiology?
Gene identification in the NOD mouse (Rainbow et al., 2008)
has also indicated genes and pathways, for example, the ion-
transporter gene Slc11a1, which does not yet have an obvious
counterpart in the human genetic studies. Slc11a1 enhances
the autoimmune diabetogenic T cell response by altering pro-
cessing and presentation of pancreatic islet antigens (Dai
et al., 2009). In addition, there are certainly more genes to be
found in humans, as not all of the familial clustering, which is
caused by both genetic and environmental factors, is explained,
with about 25% remaining to be accounted for (Clayton, 2009).
This could be due to holes in the current SNP GWAS maps or
to loci with smaller risks. However, it is not likely due to common
structural or copy number DNA variants (Wellcome Trust Case
Control Consortium, 2010).
In addition, there are plausible intrafamilial environmental and/
or stochastic factors that could alter the risk of T1D of a sibling
within a family. For example, babies gain their gut microflora
frommothers during birth and this microflora is a non-genetically
inherited, transmissible factor that could influence T1D suscep-
tibility (Cardwell et al., 2008). In the NODmouse, gut flora and its
interaction with innate immune response molecules such as the
TLR genes is an important determinant of T1D development
(Wen et al., 2008). Caesarian-section babies gain their gut flora
from the hospital room and tend to have more pathogenic,
and, therefore, immunostimulatory, bacterial levels (Penders
et al., 2006) and interestingly, it has been reported that
caesarean section is a protective factor for T1D (Cardwell
et al., 2008).
The other area that is relevant is the role of epigenetics
(Javierre et al., 2010; MacFarlane et al., 2009; Wang et al., 2009),
which provides a molecular bridge between genes and environ-
ment (MacFarlane et al., 2009;Waterland et al., 2006). Stochastic
early epigenetic imprinting that can alter gene expression as well
as environmentally-induced epigenetic changes (MacFarlane
et al., 2009; Tobi et al., 2009; Waterland et al., 2006), including
the aging process itself (Rakyan et al., 2010), could help account
for the discordance of monozygotic twins for disease (Kaminsky
et al., 2009). Recently, the first parentally imprinted susceptibility
region has been reported, involving the DLK1-MEG3 locus on
chromosome 14q32, in which expression of the maternal haplo-type of these genes is suppressed by epigenetic mechanisms
such that the risk of T1D at this locus is transmitted from fathers
only (Wallace et al., 2010). Therefore, going forward, it will be
necessary to combine studies correlating disease-associated
SNP alleles and haplotypes with gene expression and splicing,
with measurement of their methylation status. T1D genes shown
in Figure 2 are already known to have differentially-methylated
regions that affect their expression, namely INS, IL2, and IL10.
Investigating T1D candidate genes and the effects of their
alleles on downstream phenotypes, from RNA to cellular and
whole organisms, is now amajor target of research. Such exper-
iments also require the use of mousemodels to study effects and
relevance in vivo (Yamanouchi et al., 2007), with the caveats that
the models must be as close as possible genetically and physi-
ologically to the human disease (Brehm et al., 2010). However,
even the correlation of alleles and their haplotypes with RNA
expression is complex. For example, the ORMDL3 region of
chromosome 17q12 has been associated with susceptibility to
asthma (Moffatt et al., 2007), and now with T1D (Barrett et al.,
2009). In the initial asthma report, emphasis was placed on the
ORMDL3 gene (Moffatt et al., 2007), whereas more recently, it
is evident that themost disease-associated SNPs are correlating
with transcription of at least three genes in the region in addition
to ORMDL3, namely ZPBP2 and GSDMB (Verlaan et al., 2009).
Meanwhile, the initial publication in 2006 (Moffatt et al., 2007)
prompted several labs to begin to study the functions of
ORMDL3 (Breslow et al., 2010; Cantero-Recasens et al., 2010).
And yet now, perhaps GSMB is the more interesting candidate
(Verlaan et al., 2009), and the field will need to wait to see which
particular gene, or perhaps all three, are causal in asthma and
in T1D.
The assessment of the concordance of disease- and
eQTL-associated SNPs requires careful statistical evaluation
(Plagnol et al., 2009). The transcriptional and splicing complexity
of the genome is only just becoming apparent (Coulombe-Hun-
tington et al., 2009; Pickrell et al., 2010). Thankfully, technology is
still rapidly improving (Coulombe-Huntington et al., 2009; Heap
et al., 2009; Lower et al., 2009; Pickrell et al., 2010). Long-range
gene regulation is going to be common (Lower et al., 2009),
where the most disease-associated SNP (or forms of variation
such as structural variation or simple repeats) could be hundreds
of kb away from the gene(s) they act on. It is still muchmore likely
that cis-regulatory elements lie within 50 kb of a structural gene,
but researchers now need to consider not only the genes in the
immediate genomic region, but also those genes within 0.5 Mb
either side of the most associated region in case there are long-
range effects. In T1D, there are currently identified non-MHC
regions (Figure 2), with 423 genes in the immediate high-asso-
ciation interval and 790 genes in the > 1 Mb regions. In addition,
there are 167 and 433 non-protein-coding sequences in these
two categories of regions, and these could well have altered
functions owing to genome polymorphism. Fortunately, the
correlation of gene expression and regulatory components can
be investigated using a variety of recently developed genomics
technologies and approaches (Beck and Rakyan, 2008; Gaulton
et al., 2010; Park, 2009; Verlaan et al., 2009).
It is hypothesized that groups or subsets of T1D genes are
acting to compromise certain pathways in T1D, for example,
IL-2 signaling and production (Dendrou et al., 2009; LongImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 463
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Reviewet al., 2010; Tang et al., 2008), where stratification of subjects or
patients by immunophenotypes may have clinical application. In
the future, improving knowledge about the etiology of T1Dwill be
used increasingly not only to help design and select potential
therapeutics but also to monitor the effects of reagents on
etiological phenotypes or disease precursors, complementing
and informing on the use of current read-outs, namely
C-peptide, autoantibodies, or diagnosis of T1D.
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